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Abstract Traditionally, glycogen synthase (GS) has been con-
sidered to catalyze the key step of glycogen synthesis and to
exercise most of the control over this metabolic pathway. How-
ever, recent advances have shown that other factors must be
considered. Moreover, the control of glycogen deposition does
not follow identical mechanisms in muscle and liver. Glucose
must be phosphorylated to promote activation of GS. Glucose-
6-phosphate (Glc-6-P) binds to GS, causing the allosteric acti-
vation of the enzyme probably through a conformational rear-
rangement that simultaneously converts it into a better substrate
for protein phosphatases, which can then lead to the covalent
activation of GS. The potency of Glc-6-P for activation of liver
GS is determined by its source, since Glc-6-P arising from the
catalytic action of glucokinase (GK) is much more e¡ective in
mediating the activation of the enzyme than the same metabolite
produced by hexokinase I (HK I). As a result, hepatic glycogen
deposition from glucose is subject to a system of control in
which the ‘controller’, GS, is in turn controlled by GK. In con-
trast, in skeletal muscle, the control of glycogen synthesis is
shared between glucose transport and GS. The characteristics
of the two pairs of isoenzymes, liver GS/GK and muscle GS/HK
I, and the relationships that they establish are tailored to suit
speci¢c metabolic roles of the tissues in which they are ex-
pressed. The key enzymes in glycogen metabolism change their
intracellular localization in response to glucose. The changes in
the intracellular distribution of liver GS and GK triggered by
glucose correlate with stimulation of glycogen synthesis. The
translocation of GS, which constitutes an additional mechanism
of control, causes the orderly deposition of hepatic glycogen and
probably represents a functional advantage in the metabolism of
the polysaccharide.
. 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
Glycogen accumulation is a physiological response in mam-
mals to the increase in blood glucose concentration that oc-
curs after a meal. The biochemical pathway that allows the
incorporation of new glucose units into a growing glycogen
molecule is fairly well known and involves the successive ac-
tion of several proteins and enzymes. Glycogen synthase (GS)
catalyzes the addition of glucose residues to the non-reducing
end of a nascent glycogen chain through K-1,4-glycosidic
bonds using UDP-glucose (UDP-Glc) as a substrate. Tradi-
tionally, this enzyme, which catalyzes the key step of glycogen
synthesis, has been considered to exercise most of the control
over this metabolic pathway. In fact, GS activity is highly
regulated through phosphorylation at multiple sites and allo-
steric e¡ectors [1], mainly glucose-6-phosphate (Glc-6-P) [2]
and, furthermore, the reaction catalyzed by GS is rate limiting
for glycogen synthesis in all organs [3]. However, recent ad-
vances have shown that the control of glycogen deposition
does not exclusively reside in GS and other factors must be
considered. Moreover, as discussed below, the control of gly-
cogen deposition does not follow identical mechanisms in
muscle and liver (Fig. 1).
2. Di¡erences between liver and muscle glycogen metabolism
First, let us point out the main di¡erences in how glucose is
handled in liver and muscle. In the hepatocyte, extracellular
and intracellular glucose are in equilibrium due to the high
capacity of the main hepatic glucose transporter GLUT-2 [4].
Glucokinase (GK; hexokinase IV (HK IV) is the predominant
glucose-phosphorylating enzyme in hepatocytes (and in insu-
lin- and glucagon-secreting cells of the pancreas) [5,6]. GK is a
monomeric 50 kDa protein that exhibits kinetic properties
quite distinct from those of the other members of the mam-
malian HK family. It is not inhibited by its product, Glc-6-P,
and it has a sigmoidal saturation curve and a relatively low
a⁄nity for glucose (Hill coe⁄cient = 1.5^1.8, S0:5 = 2^8 mM,
depending on the species), so that the £ux through GK is
sensitive to £uctuations in the concentration of its substrate
in the physiological range [5]. In the liver, the activity of GK
is acutely modulated by a GK regulatory protein (GKRP)
that binds and inhibits GK competitively with respect to glu-
cose. The inhibitory e¡ect of GKRP is enhanced by fructose
6-phosphate and suppressed by fructose 1-phosphate, both of
which bind to GKRP and modify its a⁄nity for GK [7].
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In muscle, glucose is imported mainly by GLUT-4, a high-
a⁄nity and low-capacity glucose transporter. In the absence
of insulin GLUT-4 is localized in internal vesicles, which
translocate to the plasma membrane in response to the hor-
mone [8]. Thus, in contrast to what occurs in liver, glucose
transport in muscle is mainly insulin dependent. On the other
hand, muscle does not possess GK but expresses two isoforms
of HK [9], I and II, both of which show a low Km for glucose
(in the micromolar range) and are inhibited by low concen-
trations of Glc-6-P.
In the biochemical pathway towards glycogen synthesis,
Glc-6-P is converted successively into Glc-1-P, by phospho-
glucomutase (PGM), and then into UPD-glucose, by UDP-
glucose pyrophosphorylase (UDPGPP). This last metabolite is
the glycosyl donor in the reaction catalyzed by GS. Neither
PGM [10] nor UDPGPP [11] has tissue-speci¢c isoforms, and
therefore muscle and liver express the same forms of these two
enzymes. In contrast, two isoforms of mammalian GS have
been described. Most organs express the muscle form, whereas
the liver isoenzyme appears to be tissue speci¢c [3]. Although
the two forms are 70% identical in the amino acid sequence,
the amino- and the carboxyl-terminal, which contain the
known phosphorylation sites that regulate the activity of the
enzyme, show a much lower degree of homology [12]. The C-
terminal region of the enzyme also encompasses a stretch of
sequence that is involved in the binding of Glc-6-P [13]. These
di¡erences and their dissimilar intracellular distribution
[14,15] suggest that muscle and liver GS have distinct capaci-
ties in the control of glycogen synthesis in the respective or-
gans (Fig. 2).
Glycogen phosphorylase (GP) catalyzes the key step in gly-
cogen degradation [16], yielding Glc-1-P. GP is regulated by
allosteric mechanisms and by phosphorylation of Ser-14 by
phosphorylase kinase. The dephosphorylated form (GP b) is
less active than the phosphorylated form (GP a). As with GS,
muscle and liver express distinct GP isoforms. Liver GP, un-
like the muscle form, is more tightly controlled by phosphor-
ylation than by allosteric regulation [16], and thus not acti-
vated by AMP, whereas this compound can overcome the
e¡ect of phosphorylation on the activity of the muscle isoen-
zyme.
3. Activation of liver GS
A fundamental question in hepatic glycogen metabolism is
how an increase in blood glucose levels triggers the activation
of hepatic GS. Activation occurs through the dephosphoryla-
Fig. 1. Schematic representation of glycogen metabolism in liver and muscle. In green are shown the liver proteins and in blue the correspond-
ing muscle isoforms. G6Pase is only expressed in liver and there is no muscle isoform. In addition to the abbreviations used in the text, BE
and DBE indicate, respectively, the branching and debranching enzymes and GGN indicates glycogenin.
Fig. 2. Comparison of muscle and liver GS primary structures. The
central region, which presumably contains the catalytic residues,
shows the highest degree of identity between the two isoforms. The
known phosphorylation sites at the N-and C-terminal tails, which
show a lower degree of identity, are indicated, together with the ki-
nases that are know to phosphorylate these sites in vitro.
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tion of the enzyme, which is probably produced by type I
protein phosphatases [1]. It was suggested that unmetabolized
glucose was indirectly responsible for the activation of GS
through a sequential mechanism [17], which involved the prior
inactivation of GP. Thus, the binding of glucose to GP a
would favor its dephosphorylation and inactivation, which
in turn would relieve GS phosphatase from the allosteric in-
hibition caused by GP a, but not by GP b. Consequently, the
dephosphorylation of GP a would lead to the dephosphory-
lation and activation of GS.
However, evidence from our laboratory indicates that glu-
cose must be phosphorylated to promote activation of liver
GS. Initially, we showed that the activation of GP was not a
prerequisite for the activation of GS. This conclusion was
derived from two studies in which the treatment with fructose
[18] or lithium chloride [19] of hepatocytes isolated from
fasted rats led to the simultaneous activation of GS and
GP. Then, we showed that GS activation showed a strong
positive correlation with the intracellular levels of Glc-6-P
[20]. Later, by incubating isolated hepatocytes with di¡erent
sugar derivatives, we found that only those hexoses that can
give a phosphate ester in C6, such as glucose and 2-deoxyglu-
cose, activate GS [21].
Taken together these results indicate that the activation of
GS requires Glc-6-P. The mechanism suggested is that Glc-6-
P binds to GS causing the allosteric activation of the enzyme
through a conformational rearrangement that simultaneously
converts it into a better substrate for protein phosphatases [2].
The action of these phosphatases can then lead to the covalent
activation of GS. Therefore Glc-6-P must be considered as
both a precursor and a signal molecule to direct glucose in-
corporation into glycogen (Fig. 3).
Recent studies by our group, using cultured hepatocytes,
have shown that Glc-6-P arising from the catalytic action of
GK is much more e¡ective in mediating the activation of liver
GS than the same metabolite produced by HK I [22,23]. These
results indicate that the potency of Glc-6-P for activation of
GS is determined by its source. One reasonable explanation
for this observation would be that Glc-6-P is compartmental-
ized in at least two pools in hepatocytes. Liver GS is excluded
from the compartment where the Glc-6-P produced by HK I
is directed, while it has access to the Glc-6-P pool replenished
by the GK-mediated phosphorylation of glucose [24]. This
second pool is also accessible to other enzymes and provides
a substrate for several metabolic routes. Further evidence
along these lines was obtained from the study of hepatoma
FTO2B cells, which endogenously express liver GS and HK I,
but not GK. These cells do not synthesize glycogen, even in
the presence of high concentrations of glucose [25] or when
liver GS is overexpressed [24]. However, expression of GK
conferred to these cells the ability to synthesize and accumu-
late glycogen, as well as enhanced glycolysis [24,25]. Overex-
pression of GK in primary cultured hepatocytes greatly en-
hanced glycogen accumulation [22]. Furthermore, restoration
of normal GK levels in cultured hepatocytes from diabetic
rats improved glucose utilization and storage [26].
We have also shown that Glc-6-P arising from gluconeo-
genesis is as e¡ective in activating hepatic GS as Glc-6-P
produced by GK [27]. Therefore, the gluconeogenic pathway
and the direct phosphorylation of glucose by GK deliver their
Fig. 3. Schematic representation of the allosteric and covalent activation of GS. Binding of Glc-6-P to phosphorylated inactive GS causes a
conformational rearrangement that allosterically activates the enzyme and simultaneously exposes the phosphorylated residues of the protein.
Dephosphorylation of these residues produces an active enzyme, which does not need the presence of Glc-6-P to maintain its active conforma-
tion.
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common product to the same ‘general’ Glc-6-P pool, which
feeds the above-mentioned metabolic processes. On the other
hand, Glc-6-P from this pool can also be directed to hydro-
lysis by glucose-6-phosphatase (G6Pase), because overexpres-
sion of the catalytic subunit of this system reduces glycogen
deposition and lactate production, while it increases hydroly-
sis of Glc-6-P [28].
Nevertheless, through the use of GP inhibitors which cause
its inactivation by dephosphorylation, it has been shown that
under certain conditions GP a can play a role in controlling
the phosphorylation state of GS [29^31]. These results may be
reconciled with the main role of Glc-6-P by assuming that the
levels of active GP in£uence the GS activation state, as long
as the intracellular concentration of Glc-6-P remains constant.
However, an increase in the Glc-6-P concentration would
override the allosteric inhibition of GS phosphatase by GP
a, thus causing a corresponding increase in the levels of active
GS in cultured hepatocytes.
The ability to di¡erentiate between Glc-6-P produced by
GK or by HK I is a speci¢c feature of liver GS. The activa-
tion state of muscle GS heterologously expressed in FTO2B
cells strongly correlated with the intracellular Glc-6-P levels,
regardless of the origin of this metabolite [24].
4. Control of glycogen deposition
As mentioned before, it is generally accepted that GS is the
enzyme that catalyzes the rate-limiting step in the synthesis of
glycogen. The importance of this enzyme in the overall pro-
cess of glycogen deposition is con¢rmed by the observation
that overexpression of GS in cultured hepatocytes increases
glycogen accumulation [32]. This is the consequence of an
increase in active GS, induced by endogenous GK activity,
since more substrate is available for the Glc-6-P-dependent
dephosphorylation of GS catalyzed by phosphatases.
However, when GK is overexpressed, the increase in Glc-
6-P results in a higher degree of activation of the endoge-
nous GS, which also leads to the deposition of larger
amounts of glycogen. When both enzymes are overexpressed,
there is a combination of the two e¡ects. The positive e¡ect
of Glc-6-P in glycogen deposition is not due to a ‘push’ that
increases substrate concentration, since UDP-Glc levels are
not signi¢cantly increased in GK-overexpressing cells. An
increase in Glc-6-P produced by GK results in the dephos-
phorylation of GS molecules, and therefore in an increase in
active GS, which in turn ‘pulls’ substrate into glycogen.
These results con¢rm that the catalytic concentration of ‘ac-
tive’ GS (in the I or a form) is the key factor in glycogen
biosynthesis. When glucose is used as a substrate, this con-
centration is determined by the levels of both total GS and
GK [32].
In metabolic control analysis, the degree of control that a
given enzyme exerts over a metabolic pathway is expressed as
its control coe⁄cient. The fact that GK overexpression greatly
enhances glycogen deposition indicates that GK has a high,
positive control coe⁄cient in this process. Its experimental
measure a¡orded a value well over 1.0 [33]. Since the summa-
tion theorem dictates that the sum of the control coe⁄cients
of all enzymes in a metabolic route must equal 1.0, other
proteins of the pathway must possess high negative control
coe⁄cients. However, G6Pase, the enzyme that catalyzes the
reverse reaction of GK, has a moderately high control coef-
¢cient of 30.3 in glycogen deposition. The protein that coun-
terbalances GK is GKRP, which has a negative and high (in
absolute value) control coe⁄cient in glycogen synthesis [34].
Thus, the control coe⁄cients of both GK and GKRP in gly-
cogen synthesis are a function of their relative ratio, such that
the mechanism comprising these two proteins confers on the
hepatocyte a versatile mechanism to adjust glucose phosphor-
ylation far beyond the sensitivity and responsiveness provided
by a single sigmoidal enzyme alone.
In summary, hepatic glycogen deposition from glucose is
subject to a system of control in which the ‘controller’, GS,
is in turn controlled by GK and GKRP. This system is di¡er-
ent from phosphorylation cascades, in which an enzyme di-
rectly controls the activity of the next in the pathway. In our
system, control is exerted indirectly via the level of Glc-6-P,
which ‘switches on’ GS dephosphorylation, thus leading to its
activation.
The control of muscle glycogen synthesis, however, resides
in di¡erent steps. Measurements from transgenic animals that
overexpress a constitutively active form of rabbit muscle GS
have shown that, in skeletal muscle, the control of glycogen
synthesis is shared between glucose transport and GS [35,36].
In these studies, the authors showed that muscle GS overex-
pression increased the glycogen content of various types of
skeletal ¢bers. However, the levels of UDP-Glc substantially
decreased as a result of the increased GS activity, and the lack
of substrate limited glycogen accumulation. HK I, which ac-
counts for a high percentage of total HK activity in skeletal
muscle [37], and muscle GS are, respectively, at the beginning
and at the end of the glycogen synthesis pathway in muscle.
The high a⁄nity of HK I for glucose implies that this sugar is
readily converted into Glc-6-P upon entering the cell, and thus
the pair HK I^muscle GS is sensitive to the low concentra-
tions of glucose present in the muscle cell. This explains why
the control of glycogen deposition in muscle does not reside in
the glucose-phosphorylating capacity of the cell but rather in
the insulin-stimulated import of the sugar by the GLUT-4
transporter and in GS [35].
As mentioned above, extracellular glucose is in equilibrium
with intrahepatic glucose due to the kinetic properties of the
hepatic glucose transporter, GLUT-2 [38]. Although GK is
the main glucose-phosphorylating activity of the hepatocyte,
HK I is also present at considerable levels [39]. When blood
glucose is below V5 mM there is no signi¢cant £ux through
GK because of its high Km for glucose [39] and the action of
its regulatory protein, which further decreases the apparent
a⁄nity of GK for glucose in the hepatocyte [40]. Therefore,
under these conditions only HK I can phosphorylate glucose,
but the Glc-6-P thus produced cannot be diverted toward the
synthesis of glycogen since this metabolite does not activate
liver GS. Only when the blood sugar concentration increases
above a threshold level does GK start to produce Glc-6-P,
thus giving the signal that triggers the synthesis of hepatic
glycogen. In this case, the control of glycogen synthesis is
not exerted by glucose transport but rather by GK and GS
[32]. It thus appears that the inability of the Glc-6-P produced
by HK I to stimulate the activation of liver GS is one way for
the hepatocyte to ensure that hepatic glycogen synthesis is
only engaged when needed, which is when blood glucose levels
are high.
We conclude that the characteristics of the two pairs of
isoenzymes, liver GS/GK and muscle GS/HK, and the rela-
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tionships that they establish are tailored to suit speci¢c meta-
bolic roles of the tissues in which they are expressed.
5. Intracellular localization of enzymes
Most of the enzymes that have been described change their
intracellular localization in response to glucose, which prob-
ably constitutes an additional mechanism of control.
In the absence of the sugar, GK is localized to the nucleus
of the hepatocyte, where it is retained by GKRP, but moves
into the cytosol when the levels of glucose increase [41,42].
HK I has been shown to reversibly bind to the outer mito-
chondrial membrane through a hydrophobic N-terminal se-
quence [43]. This association, which is partly controlled by
the intracellular levels of Glc-6-P, plays a role in the regula-
tion of HK I activity in vivo. Low levels of Glc-6-P favor the
association with mitochondria and stimulate HK I activity,
while high levels have the opposite e¡ect [44].
Muscle GS concentrates in the nucleus at low glucose and
translocates to the cytosol, where it adopts a particulate pat-
tern, when the glucose concentration increases [15,45]. In con-
trast, liver GS presents a cytosolic distribution in the absence
of glucose and accumulates at the periphery of the hepatocyte
when the concentration of the hexose increases [14,46]. Glc-6-
P is responsible for both the activation and translocation of
GS [47^49]. It appears that the Glc-6-P-induced change in the
allosteric con¢guration of this enzyme which facilitates its
dephosphorylation also triggers the translocation toward the
periphery of the cell.
Changes in the intracellular distribution of liver GS and
GK triggered by glucose correlate with stimulation of glyco-
gen synthesis [50]. The translocation of these two enzymes
suggests a spatial order in the metabolism of hepatic glycogen.
In hepatocytes isolated from fasted rats the particles that can
give rise to new glycogen synthesis concentrate near the plas-
ma membrane and, initially, new glycogen is synthesized only
at the periphery of the hepatocyte. Thereafter, glycogen de-
posits grow from the periphery towards the interior of the cell
forming a crown that becomes thicker as the incubation time
with glucose increases. Nevertheless, at least while there is net
accumulation of glycogen, the synthesis of the polysaccharide
is always active near the plasma membrane. Previously syn-
thesized glycogen moves towards the center of the cell and
newly synthesized molecules take its place. As the synthesis
of the polysaccharide progresses, glycogen synthesis becomes
active at internal sites of the hepatocyte, in addition to the
region close to the plasma membrane [51]. GS distribution
closely resembles that of glycogen, strongly suggesting that
after the initial movement to the cellular cortex and while
the deposition of glycogen is active, GS remains bound to
its substrate and product (Fig. 4).
Glycogen degradation also seems to take place in an orderly
Fig. 4. Intracellular distribution of GS and glycogen in cultured hepatocytes. GS (panels A^C) and glycogen (panels D^F) were detected with
speci¢c antibodies in cultured rat hepatocytes, which had been incubated with 30 mM glucose for 0 (panels A and D), 3 (panels B and E) and
6 h (panels C and F). The distribution of GS closely resembles that of glycogen.
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fashion. When cultured hepatocytes with full glycogen re-
serves are depleted of glucose, GS patches gradually become
smaller but remain at the cell periphery, suggesting that the
remaining undegraded glycogen is also localized there. The
GP-mediated phosphorolysis of glycogen might proceed ex-
clusively from the interior to the exterior of the hepatocyte
or simultaneously throughout the cytoplasm. However, in the
latter case, remaining glycogen particles must move towards
the hepatocyte periphery as the degradation of the polysac-
charide progresses, in such a way that after an extensive de-
pletion, the very few remaining glycogenogenic particles are
located near the plasma membrane. The observation that the
molecules of liver glycogen are synthesized in a de¢ned order
and degraded in the reverse order, such that glucose units
incorporated ¢rst are released last during glycogenolysis and
vice versa [52], favors the latter hypothesis. This ‘ordered’
deposition and degradation of glycogen might represent a
functional advantage in the metabolism of the polysaccharide
or it might simply enable the hepatocyte to store large
amounts of glycogen.
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